Arterial Endothelium & Atherogenesis
Live Particle Trafficking
Intact Lp(a) Particles
Ox-Lp(a) Subendothelial Plaque
Therapeutic Silencer (ASO/siRNA)
Circulating Knockdown & MACE Trajectory
24-Month Projection
Peak Lp(a) Knockdown
80%
Steady-State Lp(a)
37 nmol/L
Macrophage Foam Flux Reduction
74%
Projected MACE RRR
21.5%
Competitive Clinical Pipeline: Late-Stage Lipoprotein(a) Interventions
Drug Candidate & Sponsor
Modality & Target
Typical Dosing
Mean Knockdown
Key Clinical Trial
Pelacarsen Novartis
GalNAc-conjugated ASO (apo(a) mRNA)
80 mg Q4W SC
80%
Phase 3 Lp(a)HORIZON (CV Outcomes)
Olpasiran Amgen
GalNAc-conjugated siRNA (apo(a) mRNA)
225 mg Q12W SC
95%
Phase 3 OCEAN(a) (CV Outcomes)
Lepodisiran Eli Lilly
GalNAc-conjugated siRNA (apo(a) mRNA)
608 mg Q24W SC
94%
Phase 3 ACCLAIM-Lp(a) (CV Outcomes)
Muvalaplin Eli Lilly
Small molecule oral apo(a)-apoB disruptor
Once daily Oral
65-85%
Phase 2 KRAKEN Study